Floatz Rating
B57/100
Confidence
Indicative
Sponsor
CHU de Quebec-Universite Laval
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01653925CT.gov Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its Progression | — | Active Not Recruiting | — | — | — |
NCT00298155CT.gov Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| AVOLVE (this asset) | CHU de Quebec-Universite Laval | P2 | B · 57 |
| Docetaxel | Merck Sharp & Dohme LLC | P4 | BBB |
| Degarelix | Novartis Pharmaceuticals | P4 | BBB |
| Prednisone | Merck Sharp & Dohme LLC | P3 | BBB |
| Abiraterone | Qilu Pharmaceutical Co., Ltd. | P3 | BB |
| Leuporelin | Dana-Farber Cancer Institute | P4 | BB |
| Radium Ra-223 | Bayer | P3 | BB |
| Prednisolone | Eli Lilly and Company | P3 | BB |
| Gozetotide | Telix Pharmaceuticals (Innovations) Pty Limited | P3 | BB |
+42 more in the Prostate Neoplasm cohort
Other indications for AVOLVE
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Cancer | — | P4 | BB · 71 |
| Benign Prostatic Hyperplasia | — | P4 | BB · 68 |
| Erectile Dysfunction | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. AVOLVE in Prostate Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/avolve-prostate-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →